Crossmark

Salinomycin decreases feline sarcoma and carcinoma cell viability when combined with doxorubicin

Crossref DOI link: https://doi.org/10.1186/s12917-019-1780-5

Published Online: 2019-01-24

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Borlle, Lucia

Dergham, Abdo

Wund, Zacharie

Zumbo, Brittany

Southard, Teresa

Hume, Kelly R. https://orcid.org/0000-0001-9935-2118
Funding

Funding for this research was provided by:

Cornell Feline Health Center (n/a)

College of Veterinary Medicine, Cornell University (n/a)

Winn Feline Foundation (MT14-013)
License Information

Text and Data Mining valid from 2019-01-24
More Information

Article History

Received: 6 February 2018

Accepted: 14 January 2019

First Online: 24 January 2019

Ethics approval and consent to participate

: Animal research was approved by the Cornell University Institutional Care and Use Committee, protocol #2011–0112. Written and/or verbal consent was obtained from the owners of cats involved in this study.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.